He describes the asset, which has an extended half life and is designed to only inhibit the active form of C1s, and contrasts it with other medicines on the market today. Plus, the rationale for in-licensing a bispecific fusion protein that targets BDCA2 and BAFF/APRIL.

He discusses the causes of the rapid bounce biotech has witnessed over the last handful of months, his take on 2026, including the IPO environment, private vs public companies, areas of interest, and more.

Co-Founder and CEO Daniel Getts walks us through the platform, which is delivered via LNPs. The lead programs target TROP2, HER2, and GPC3.

CEO James Field and CSO Angus Sinclair discuss the Nectin-4 bi-specific, which is meant to have increased selectivity and potency and will compete with ADCs that are already on the market. Plus, how they are using their ML/AI expertise to help Sanofi with new programs.

Founder and CEO Michelle Lee highlights the key distinction between Medra and other automated lab equipment, which is that Medra's platform is designed to sense and understand its environment and use that knowledge to make its own intelligent decisions.

He talks about Kymera's dosing methodology, and recaps the data from a degradation, biomarker, and clinical outcomes standpoint. Plus, next steps in STAT6, and thoughts on the platform in general and the field more broadly.

CEO Abe Ceesay describes Rapport's precision neuroscience approach of targeting the AMPA receptor specifically through TARPγ8, and explains why the company took the extra step of tracking an electrographic biomarker in its phase 2a study in addition to seizure frequency. Plus, next steps and additional indications.

Founder and CEO Kevin Friedman describes Kelonia's approach, which uses a lentivirus for delivery, and discusses differentiating features of in vivo CAR-T platforms. He walks us through today's data and highlights what is next. Coverage brought to you by

Founder and CEO Hervé Affagard walks us through how this treatment works and highlights the ASH presentation and one year survival data the company has accrued. Plus, how compassionate use is going in the United States. Coverage brought to you by

The therapy has shown single agent efficacy in patients who are refractory to BTKs. Plus, an update on global studies of the BCR-ABL/KIT, olverembatinib, and highlighting Ascentage's EED inhibitor. Coverage brought to you by

He describes the science behind ITK, and goes over ASH data in r/r T-cell lymphoma, where the company is already enrolling a pivotal study. Plus, why the profile of ITK in oncology gives him confidence in its utility for autoimmune disease, and highlighting atopic dermatitis data that will be coming in January. Coverage brought to you by

He describes two studies Nurix presented for bexobrutideg at ASH, and also discusses the pivotal DAYBreak study that has already been initiated. Plus, his take on today's STAT6 competitor data and how he feels about IRAK4. Coverage brought to you by

He describes the data, and walks us through two different dosing strategies. Plus, the business case for this simple biologic, and thinking about other antigens and cancer types. Coverage brought to you by

He describes how this asset binds to the extracellular domain and therefore can work for both wild type patients and those with mutations. Plus, recent regulatory news on zipalertinib and when to expect to see autoimmune data. Coverage brought to you by

Co-Founder and CEO Sarah Hein discusses the CD5 target and this type of cancer, and highlights what is next. March, a startup from the Houston area, has raised over $50 million up to this point. Coverage brought to you by

He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion. Coverage brought to you by

She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer. Coverage brought to you by

He describes how Rigel became focused on both IRAK 1 and 4, a novel mechanism in the area of hematology, and what is next for the company after the ASH presentation. Coverage brought to you by

Shares an update on the company's ASH data, and also on plans to move into earlier lines of treatment. A registrational study is already set to begin in early 2026. Coverage brought to you by

He says that this interim update, which is studying 50mg every 4 weeks for up to 6 treatments, is showing response rates in line with an earlier dose escalation study that was presented at ASH last year. Plus, a quick regulatory update on bitopertin. Coverage brought to you by